Skip to main content

Advertisement

SpringerLink
Log in

Visfatin levels and intima-media thicknesses in rheumatic diseases

  • Original Article
  • Published:
Clinical Rheumatology Aims and scope Submit manuscript

Abstract

Chronic inflammatory rheumatic diseases lead to increased prevalence of atherosclerosis. However, this early and accelerated atherosclerosis cannot be explained by traditional cardiovascular risk factors alone. The permanent overexpression of cellular adhesion molecules and pro-inflammatory cytokines in chronic inflammatory conditions may participate in accelerated atherosclerosis. Visfatin, a novel adipocytokine, has a potential insulin-like action and pro-inflammatory effects. Therefore, the aim of the study was to determine serum visfatin level and its association with common carotid intima-media thickness (IMT), which is a predictor of atherosclerosis, in patients with rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), systemic sclerosis (SSc), and Behçet’s disease (BD). The study involved 29 RA, 26 SLE, 25 SSc, 30 BD patients, and 29 healthy controls (HC). Serum levels of TNF-α, IL-6, and visfatin were analyzed using enzyme-linked immunosorbent assay method and homeostasis model assessment for insulin resistance (HOMA-IR) indexes, and IMTs were determined. Serum visfatin level was higher in the RA group than all the other groups. In addition, visfatin level was higher in the active BD subgroup than the inactive BD subgroup. In the study groups, visfatin levels were not correlated with HOMA-IR indexes and IMTs. Whereas visfatin serum concentration was not associated with insulin resistance and carotid atherosclerosis in selected rheumatic diseases, it was higher in the RA and active BD groups, but not in the SLE and SSc groups. Visfatin levels may be associated with Th1/Th2 balance. Further studies are needed for more precise elucidation of the pro-inflammatory activities of visfatin.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Sattar N, McCarey DW, Capell H, McInnes IB (2003) Explaining how “high-grade” systemic inflammation accelerates vascular risk in rheumatoid arthritis. Circulation 108:2957–2963

    Article  PubMed  Google Scholar 

  2. Symmons DP, Jones MA, Scott DL, Prior P (1998) Longterm mortality outcome in patients with rheumatoid arthritis: early presenters continue to do well. J Rheumatol 25:1072–1077

    PubMed  CAS  Google Scholar 

  3. Ward MM (1999) Premature morbidity from cardiovascular and cerebrovascular diseases in women with systemic lupus erythematosus. Arthritis Rheum 42:338–346

    Article  PubMed  CAS  Google Scholar 

  4. Thompson T, Sutton-Tyrrell K, Wildman RP et al (2008) Progression of carotid intima-media thickness and plaque in women with systemic lupus erythematosus. Arthritis Rheum 58:835–842

    Article  PubMed  CAS  Google Scholar 

  5. Hettema ME, Zhang D, de Leeuw K et al (2008) Early atherosclerosis in systemic sclerosis and its relation to disease or traditional risk factors. Arthritis Res Ther 10:R49

    Article  PubMed  Google Scholar 

  6. Oztürk MA, Oktar SO, Unverdi S et al (2006) Morphologic evidence of subclinical atherosclerosis obtained by carotid ultrasonography in patients with Behcet’s disease. Rheumatol Int 26:867–872

    Article  PubMed  Google Scholar 

  7. Full LE, Ruisanchez C, Monaco C (2009) The inextricable link between atherosclerosis and prototypical inflammatory diseases rheumatoid arthritis and systemic lupus erythematosus. Arthritis Res Ther 11:217

    Article  PubMed  Google Scholar 

  8. Koca SS, Karaca I, Yavuzkir MF et al (2009) Insulin resistance is related with oxidative stress in systemic lupus erythematosus. Anadolu Kardiyol Derg 9:23–28

    PubMed  Google Scholar 

  9. Lang CH, Dobrescu C, Bagby GJ (1992) Tumor necrosis factor impairs insulin action on peripheral glucose disposal and hepatic glucose output. Endocrinology 130:43–52

    Article  PubMed  CAS  Google Scholar 

  10. Vozarova B, Weyer C, Hanson K, Tataranni PA, Bogardus C, Pratley RE (2001) Circulating interleukin-6 in relation to adiposity, insulin action, and insulin secretion. Obes Res 9:414–417

    Article  PubMed  CAS  Google Scholar 

  11. Fernández-Real JM, Ricart W (2003) Insulin resistance and chronic cardiovascular inflammatory syndrome. Endocr Rev 24:278–301

    Article  PubMed  Google Scholar 

  12. Gonzalez-Gay MA, Gonzalez-Juanatey C, Lopez-Diaz MJ et al (2007) HLA-DRB1 and persistent chronic inflammation contribute to cardiovascular events and cardiovascular mortality in patients with rheumatoid arthritis. Arthritis Rheum 57:125–132

    Article  PubMed  CAS  Google Scholar 

  13. Samal B, Sun Y, Stearns G, Xie C, Suggs S, McNiece I (1994) Cloning and characterization of the cDNA encoding a novel human pre-B-cell colony-enhancing factor. Mol Cell Biol 14:1431–1437

    PubMed  CAS  Google Scholar 

  14. Moschen AR, Kaser A, Enrich B et al (2007) Visfatin, an adipocytokine with proinflammatory and immunomodulating properties. J Immunol 178:1748–1758

    PubMed  CAS  Google Scholar 

  15. Ognjanovic S, Bryant-Greenwood GD (2002) Pre-B-cell colony-enhancing factor, a novel cytokine of human fetal membranes. Am J Obstet Gynecol 187:1051–1058

    Article  PubMed  CAS  Google Scholar 

  16. Jia SH, Li Y, Parodo J et al (2004) Pre-B cell colony-enhancing factor inhibits neutrophil apoptosis in experimental inflammation and clinical sepsis. J Clin Invest 113:1318–1327

    PubMed  CAS  Google Scholar 

  17. Ye SQ, Simon BA, Maloney JP et al (2005) Pre-B cell colony-enhancing factor as a potential novel biomarker in acute lung injury. Am J Respir Crit Care Med 171:361–370

    Article  PubMed  Google Scholar 

  18. Otero M, Lago R, Gomez R et al (2006) Changes in plasma levels of fat-derived hormones adiponectin, leptin, resistin and visfatin in patients with rheumatoid arthritis. Ann Rheum Dis 65:1198–1201

    Article  PubMed  CAS  Google Scholar 

  19. Fukuhara A, Matsuda M, Nishizawa M et al (2005) Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science 307:426–430

    Article  PubMed  CAS  Google Scholar 

  20. Berndt J, Klöting N, Kralisch S et al (2005) Plasma visfatin concentrations and fat depot-specific mRNA expression in humans. Diabetes 54:2911–2916

    Article  PubMed  CAS  Google Scholar 

  21. Chen MP, Chung FM, Chang DM et al (2006) Elevated plasma level of visfatin/pre-B cell colony-enhancing factor in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 91:295–299

    Article  PubMed  CAS  Google Scholar 

  22. Kim SR, Bae YH, Bae SK et al (2008) Visfatin enhances ICAM-1 and VCAM-1 expression through ROS-dependent NF-kappaB activation in endothelial cells. Biochim Biophys Acta 1783:886–895

    Article  PubMed  CAS  Google Scholar 

  23. Dahl TB, Yndestad A, Skjelland M et al (2007) Increased expression of visfatin in macrophages of human unstable carotid and coronary atherosclerosis: possible role in inflammation and plaque destabilization. Circulation 115:972–980

    Article  PubMed  CAS  Google Scholar 

  24. Arnett FC, Edworthy SM, Bloch DA et al (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315–324

    Article  PubMed  CAS  Google Scholar 

  25. Hochberg MC (1997) Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 40:1725

    Article  PubMed  CAS  Google Scholar 

  26. LeRoy EC, Medsger TA Jr (2001) Criteria for the classification of early systemic sclerosis. J Rheumatol 28:1573–1576

    PubMed  CAS  Google Scholar 

  27. International Study Group for Behcet’s Disease (1990) Criteria for diagnosis of Behcet’s disease. Lancet 335:1078–1080

    Google Scholar 

  28. Leeb BF, Andel I, Sautner J et al (2005) Disease activity measurement of rheumatoid arthritis: comparison of the simplified disease activity index (SDAI) and the disease activity score including 28 joints (DAS28) in daily routine. Arthritis Rheum 53:56–60

    Article  PubMed  Google Scholar 

  29. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH (1992) Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 35:630–640

    Article  PubMed  CAS  Google Scholar 

  30. Gladman D, Ginzler E, Goldsmith C et al (1996) The development and initial validation of the systemic lupus international collaborating clinics/American college of rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum 39:363–369

    Article  PubMed  CAS  Google Scholar 

  31. Della Rossa A, Valentini G, Bombardieri S et al (2001) European multicentre study to define disease activity criteria for systemic sclerosis. I. Clinical and epidemiological features of 290 patients from 19 centres. Ann Rheum Dis 60:585–591

    Article  PubMed  CAS  Google Scholar 

  32. Medsger TA Jr, Silman AJ, Steen VD et al (1999) A disease severity scale for systemic sclerosis: development and testing. J Rheumatol 26:2159–2167

    PubMed  Google Scholar 

  33. Isik A, Koca SS, Ustundag B, Selek S (2007) Decreased total antioxidant response and increased oxidative stress in Behcet’s disease. Tohoku J Exp Med 212:133–141

    Article  PubMed  Google Scholar 

  34. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC (1985) Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412–419

    Article  PubMed  CAS  Google Scholar 

  35. Lago F, Dieguez C, Gomez-Reino J, Gualillo O (2007) The emerging role of adipokines as mediators of inflammation and immune responses. Cytokine Growth Factor Rev 18:313–325

    Article  PubMed  CAS  Google Scholar 

  36. Pagano C, Pilon C, Olivieri M et al (2006) Reduced plasma visfatin/pre-B cell colony-enhancing factor in obesity is not related to insulin resistance in humans. J Clin Endocrinol Metab 91:3165–3170

    Article  PubMed  CAS  Google Scholar 

  37. Curat CA, Wegner V, Sengenès C et al (2006) Macrophages in human visceral adipose tissue: increased accumulation in obesity and a source of resistin and visfatin. Diabetologia 49:744–747

    Article  PubMed  CAS  Google Scholar 

  38. Gonzalez-Gay MA, Vazquez-Rodriguez TR, Garcia-Unzueta MT et al (2010) Visfatin is not associated with inflammation or metabolic syndrome in patients with severe rheumatoid arthritis undergoing anti-TNF-alpha therapy. Clin Exp Rheumatol 28:56–62

    PubMed  CAS  Google Scholar 

  39. Vadacca M, Margiotta D, Rigon A et al (2009) Adipokines and systemic lupus erythematosus: relationship with metabolic syndrome and cardiovascular disease risk factors. J Rheumatol 36:295–297

    Article  PubMed  CAS  Google Scholar 

  40. Brentano F, Schorr O, Ospelt C et al (2007) Pre-B cell colony-enhancing factor/visfatin, a new marker of inflammation in rheumatoid arthritis with proinflammatory and matrix-degrading activities. Arthritis Rheum 56:2829–2839

    Article  PubMed  CAS  Google Scholar 

  41. Lacraz S, Nicod L, Galve-de Rochemonteix B, Baumberger C, Dayer JM, Welgus HG (1992) Suppression of metalloproteinase biosynthesis in human alveolar macrophages by interleukin-4. J Clin Invest 90:382–388

    Article  PubMed  CAS  Google Scholar 

  42. Zhang Y, McCluskey K, Fujii K, Wahl LM (1998) Differential regulation of monocyte matrix metalloproteinase and TIMP-1 production by TNF-alpha, granulocyte-macrophage CSF, and IL-1 beta through prostaglandin-dependent and -independent mechanisms. J Immunol 161:3071–3076

    PubMed  CAS  Google Scholar 

  43. Song EK, Lee YR, Yu HN et al (2008) Extracellular NAD is a regulator for FcgammaR-mediated phagocytosis in murine macrophages. Biochem Biophys Res Commun 367:156–161

    Article  PubMed  CAS  Google Scholar 

  44. Bogdan C, Vodovotz Y, Nathan C (1991) Macrophage deactivation by interleukin 10. J Exp Med 174:1549–1555

    Article  PubMed  CAS  Google Scholar 

  45. Rho YH, Solus J, Sokka T et al (2009) Adipocytokines are associated with radiographic joint damage in rheumatoid arthritis. Arthritis Rheum 60:1906–1914

    Article  PubMed  CAS  Google Scholar 

  46. Pay S, Abbasov T, Erdem H et al (2007) Serum MMP-2 and MMP-9 in patients with Behçet’s disease: do their higher levels correlate to vasculo-Behçet’s disease associated with aneurysm formation? Clin Exp Rheumatol 25:70–75

    Google Scholar 

Download references

Disclosures

None

Author information

Authors and Affiliations

  1. Department of Rheumatology, Faculty of Medicine, Firat University, Elazig, Turkey

    Metin Ozgen, Suleyman Serdar Koca & Ahmet Isik

  2. Department of Endocrinology, Faculty of Medicine, Firat University, Elazig, Turkey

    Kader Aksoy

  3. Department of Cardiology, Faculty of Medicine, Firat University, Elazig, Turkey

    Necati Dagli

  4. Department of Biochemistry, Faculty of Medicine, Firat University, Elazig, Turkey

    Bilal Ustundag

Authors
  1. Metin Ozgen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Suleyman Serdar Koca
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kader Aksoy
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Necati Dagli
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Bilal Ustundag
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Ahmet Isik
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Suleyman Serdar Koca.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ozgen, M., Koca, S.S., Aksoy, K. et al. Visfatin levels and intima-media thicknesses in rheumatic diseases. Clin Rheumatol 30, 757–763 (2011). https://doi.org/10.1007/s10067-010-1649-2

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10067-010-1649-2

Keyword

Search

Navigation